New First-Line Option for Advanced ALK-Positive Lung Cancer

(MedPage Today) -- The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.
Approval was based on results...